Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488]

The authors regret that the dosage details for trastuzumab in the original publication were incorrectly given as 8 and 6 mg/m2.

Source: European Journal of Cancer - February 18, 2021 Category: Cancer & Oncology Authors: Min-Hee Ryu, Changhoon Yoo, Jong Gwang Kim, Baek-Yeol Ryoo, Young Soo Park, Sook Ryun Park, Hye-Suk Han, Ik Joo Chung, Eun-Kee Song, Kyung Hee Lee, Seok Yun Kang, Yoon-Koo Kang Tags: Corrigendum Source Type: research